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On November 4, 2015, the Cardiovascular Risks SRP, participants from the JSC, HQ, and 
NRESS participated in a WebEx/teleconference.  The purpose of the call (as stated in the 
Statement of Task) was to allow the SRP members to: 
 
1. Receive an update from the HRP Chief Scientist (or designee) on the status of NASA’s 
current and future exploration plans and the impact these will have on the HRP. 
2. Receive an update on any changes within the HRP since the 2014 SRP meeting. 
3. Receive an update by the Element or Project Scientist(s) since the 2014 SRP meeting. 
4. Participate in a discussion with the HRP Chief Scientist (or designee) and the Element 
regarding possible topics to be addressed at the next SRP meeting. 
 
Based on the presentations and the discussion during the WebEx/teleconference, the SRP would 
like to relay the following information to Dr. Shelhamer, the HRP Chief Scientist. 
 
General Comments:  
1. Overall, the SRP thinks the quality of the WebEx/teleconference was excellent.  The 
three presentations were easy to hear, and the online presentation system worked well. It 
was organized well, with minimal delay between talks. 
 
2. All three presenters (Dr. Hather, Dr. Norsk, and Dr. Stenger) did a fine job fitting a 
tremendous amount of data within a two-hour timeframe and the work being done is 
laudable. 
 
3. Dr. Stenger’s presentation was presented in a clear, logical order and highlighted recent 
progress in the research portfolio.  The SRP found it helpful that papers were referenced 
in the presentation slides, and also found it beneficial having the presentations sent early, 
since much more has happened in the past year than can be compressed into a two hour 
presentation. 
 
4. For future meetings, the SRP would like more specific references to papers with high 
quality new data to provide a background for the SRP prior to the meeting. 
 
Specific Comments Regarding the Orthostatic Intolerance (OI) Risk: 
1. With regards to OI Risk for a Mars mission, the suitability of the current countermeasures 
depends largely upon the mission requirements for the astronauts (and upon requirements 
for astronaut performance in an emergency).  Therefore, the researchers need to have the 
best projection as to what is planned for the team upon touchdown.  For instance, if the 
plan for the astronauts is to rest and recover for 24-48 hours, then compression garments 
and acclimatization may be suitable.  However, if they may be asked to exit the vehicle 
(such as in an emergency), then perhaps additional countermeasures (EVA suit design, 
etc.) will be needed.  If such procedures and protocols have not been developed, then the 
SRP thinks these should at least be outlined to the best of NASA’s ability at this time, so 
that the researchers can get a head start on developing countermeasures for these 
contingencies. 
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2. To adequately assess the OI risk mitigation, it will be helpful in the future to present the 
continuous blood pressure data (in addition to heart rate data on landing day) as it 
pertains to the Functional Field tests and the promising mitigation of OI risk with 
compression garments.  Some of the concerns expressed regarding the Portapres data can 
likely be mitigated with analyses that focus on acute changes from a reliable baseline 
reference. 
 
3. Impaired vision in the VIIP studies was appropriately presented adjacent to the OI 
presentation.  Obviously, centrifugal countermeasures to avoid visual impairment will 
also ameliorate OI.  The SRP would like it noted that almost any treatment to diminish 
vascular or cerebrospinal fluid pressure on the eye will also affect OI.  It is possible that 
diuretics during microgravity might improve OI if fluid is repleted prior to return to 
gravity.   
 
Specific Comments Regarding the Cardiac Rhythm (Arrhthmia) Risk: 
1. The SRP requires more specific information regarding best estimates, given current and 
projected technology, regarding the amount of time in transit to Mars, on Mars, and on 
return from Mars.  We also need more information regarding the radiation environment 
during these three phases of the Mars mission (e.g., Curiosity Rover data). Finally, the 
SRP needs data regarding estimated spacecraft attenuation of radiation during the three 
phases of the Mars mission to estimate the risk of radiation induced cardiovascular 
disease.  This could be provided in a briefing from the Space Radiation Program Element 
and the Space Human Factors Engineering project at a future SRP meeting. 
 
2. There is concern that the radiation outside of low Earth orbit might impair vascular 
endothelial function.  Endothelial damage might be diminished by antioxidants, but there 
is concern from vitamin E studies that antioxidants might increase cancer risks.  
However, low levels of radiation are unlikely to cause serious damage to the 
endothelium.  Some have suggested that a 3% cancer risk increase from radiation would 
not be acceptable.  Knowledge of the level of radiation that will be tolerated might 
determine whether radiation induced endothelial damage is a problem that should be 
addressed. 
 
3. Dr. Stenger mentioned interesting research being performed on both risk estimation for 
astronauts (PI: Levine) and vascular injury basic science (PI: Natarajan).  The SRP would 
benefit from an update on this work to help with our evaluation process during future 
SRP meetings. 
 
 
 
 
